Deutsche Bank Downgrades ABIOMED (ABMD) to Hold

Deutsche Bank analyst Pito Chickering downgraded ABIOMED (NASDAQ: ABMD) from Buy to Hold with a price target of $388.00 (from $355.00).

For an analyst ratings summary and ratings history on ABIOMED click here. For more ratings news on ABIOMED click here.

Shares of ABIOMED closed at $377.82 yesterday.

You May Also Be Interested In

• AEON Biopharma, Inc (AEON) PT Lowered to $1.20 at H.C. Wainwright
• BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
• Intuit (INTU) PT Lowered to $430 at Mizuho